Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Incyte Tumbles On More Jakafi Trial Terminations

This article was originally published in Scrip

Executive Summary

Incyte Corporation is discontinuing all ongoing trials for its Janus kinase inhibitor, Jakafi (ruxolitinib), in solid tumors following poor results in a Phase III study in metastatic pancreatic cancer and in a recently suspended Phase II colorectal cancer trial.

You may also be interested in...



Incyte Further Enhances IO Pipeline With Calithera's Arginase Inhibitor

In its second cancer deal in two months, Incyte licenses a first-in-class asset expected to offer potential cancer immunotherapy synergy with IDO1 and checkpoint inhibition.

Sanofi Could Pursue Other Oncology M&A Targets After Medivation Loss

Losing Medivation could end up being a winning proposition for the French pharma if it can boost its cancer franchise another way, like by acquiring its partner in multiple collaborations Regeneron or making a less expensive takeout, such as Incyte or Ariad.

Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?

More and larger M&A deals could boost public biopharmaceutical companies, so investors will watch closely to see if Pfizer's $14bn Medivation acquisition kicks off a widespread spending spree. Speculation about who'll be bought next is in full swing.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC064485

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel